Panelists all agree that there needs to be evidence and guidelines for both payers and providers. There are not enough resources to try every drug on every patient. Although it will be costly, there needs to be evidence on putting these drugs together as combinations.
Panelists all agree that there needs to be evidence and guidelines for both payers and providers. There are not enough resources to try every drug on every patient. Although it will be costly, there needs to be evidence on putting these drugs together as combinations. “We have the American ingenuity and the wherewithal that we’ll find better ways to do it, or other drugs that come along that are less expensive in the same category,” said Dr Crawford. “I think we really owe that to men with advance state prostate cancer to make that step and start doing it.” “I think there is a blend here of continuing to do the envelope-pushing combination strategies,” said Dr George. “With cost to the wind, let’s try to cure the disease because that’s going to be the most cost-effective manner of managing these patients in the long-run anyway.”
Dr Shore offers his rebuttal by saying he thinks that a real issue is having patients reimbursed for all of the expensive newly approved agents. He says, by law, if there is a level 2 recommendation by the National Comprehensive Cancer Network the Centers for Medicare & Medicaid Services has to reimburse which is important to the payer population
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
House lawmakers are expected to advance a contracting ban today on 5 Chinese research firms; US government officials temporarily relaxed strict guidelines on how laboratories handle, store, and transport H5N1 bird flu samples; a recent report found that the number of abortions occurring in the US continued to grow despite bans.
Read More